Komplexiertes oder freies prostataspezifisches Antigen: welche Komponente sollte zur Differenzierung zwischen benigner Prostatahyperplasie und Prostatakarzinom bestimmt werden?. Complexed or Free Prostate Specific Antigen: Which Component Should be Determined to Improve the Differentiation between Benign Prostatic Hyperplasia and Prostate Cancer?
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.